Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma
Purpose: To identify new novel biomarkers for predicting the efficacy of concurrent chemoradiotherapy(CCRT) in cervical squamous cell carcinoma(CESC). Methods: Gene expression datasets GSE56363, GSE5787, and GSE168009 were analyzed to identify candidate genes to predict the efficacy of CCRT in CESC....
Main Authors: | Ge Hu, Ying Xiao, Chanchan Ma, Jinyun Wang, Xiaotao Qian, Xiaowei Wu, Fengqin Zhu, Shiying Sun, Junchao Qian |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-07-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023052192 |
Similar Items
-
Biomarkers of Favorable vs. Unfavorable Responses in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy
by: Hsin-Hua Lee, et al.
Published: (2022-05-01) -
HIF-1α Expression Increases Preoperative Concurrent Chemoradiotherapy Resistance in Hyperglycemic Rectal Cancer
by: Yi-Jung Huang, et al.
Published: (2022-08-01) -
Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
by: Chengxin Liu, et al.
Published: (2023-05-01) -
A Comprehensive RNA Expression Signature for Cervical Squamous Cell Carcinoma Prognosis
by: Jie Xiong, et al.
Published: (2019-01-01) -
Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma
by: Sadia Minhas, et al.
Published: (2017-03-01)